07:00 , Aug 3, 2015 |  BioCentury  |  Finance

Taiwan's post-bubble prognosis

More than a year after BioCentury chronicled investor enthusiasm for biotechs in Taiwan, the bubble has deflated. It's tempting to blame the downturn simply on retail investors who didn't get up to speed as quickly...
07:00 , May 9, 2011 |  BC Week In Review  |  Financial News

Crown BioScience completes venture financing

Crown BioScience Inc. , Santa Clara, Calif.   Business: Supply/Service   Date completed: 5/4/11   Type: Venture financing   Raised: $28.8 million   Investors: OrbiMed Advisors Caduceus Asia Partners Fund; Argonaut Private Equity; CID Group;...
23:42 , May 4, 2011 |  BC Extra  |  Financial News

Crown raises $28.8 million

CRO Crown Biosciences Inc. (Santa Clara, Calif.) raised $28.8 million in a series C round led by OrbiMed Advisors Caduceus Asia Partners Fund; Argonaut Private Equity; CID Group; IBT; and CDIB Capital Investment. Existing shareholders...
07:00 , Sep 20, 2010 |  BC Week In Review  |  Company News

Eddingpharm, Eddingpharm board of directors update

Eddingpharm Inc. , Shanghai, China   Business: Cancer   Appointed: Nancy Chang, chairman and senior managing director at OrbiMed Advisors LLC's Caduceus Asia Partners Fund; and Brian Halak, partner at Domain Associates LLC  ...
07:00 , Sep 20, 2010 |  BioCentury  |  Finance

Rule of 3

OrbiMed Advisors is willing to put up money from its new $550 million fund when it expects a company can get a drug candidate approved within three years. The first example of that strategy is...